Marla Dubinsky
New York, NYNPI 1790741718
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $832,334 of the $1,351,136 with a category attached, or 61.6%. 27 manufacturers reported payments, led by Pfizer at 32.0% of the total.
Across 730 payments — averaging $1850.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$432K
- AbbVie$358K
- Eli Lilly$161K
- Johnson & Johnson$106K
- Sanofi$45K
- Merck$36K
- plus $212K from 21 others
Across 159 payments — averaging $1168.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$177K
- Janssen Research & Development, LLC$5K
- UCB, Inc.$3K
- AbbVie$550
What the payments were for
- Consulting fees$832,33462%
- Speaking & faculty fees$392,14929%
- Grants$10,0001%
- Travel & lodging$106,0388%
- Food & beverage$9,7491%
- Education$8660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 130 | $432,414 |
| AbbVie | 270 | $357,985 |
| Eli Lilly | 109 | $161,388 |
| Johnson & Johnson | 83 | $105,953 |
| Sanofi | 6 | $44,768 |
| Merck | 23 | $36,138 |
| Janssen Scientific Affairs, LLC | 18 | $24,962 |
| Bristol Myers Squibb | 8 | $24,440 |
| E.r. Squibb & Sons, L.L.C. | 7 | $23,357 |
| Celltrion USA Inc. | 9 | $23,298 |
| Lilly USA, LLC | 10 | $20,806 |
| Whitehall International Inc | 3 | $19,572 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $13,125 |
| Gilead | 2 | $7,110 |
| UCB, Inc. | 1 | $7,080 |
| Astrazeneca UK Limited | 3 | $7,052 |
| Regeneron Healthcare Solutions, Inc. | 5 | $6,636 |
| Genentech, Inc. | 5 | $5,749 |
| Boehringer Ingelheim International GmbH | 5 | $5,739 |
| Janssen Global Services, LLC | 2 | $5,375 |
| Celltrion, Inc. | 1 | $3,990 |
| Mesoblast, Inc. | 1 | $3,700 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $3,100 |
| Takeda | 1 | $2,298 |
| Janssen Research & Development, LLC | 3 | $2,170 |
| Sanofi US Services Inc. | 2 | $1,828 |
| Boehringer Ingelheim | 11 | $1,103 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.